The Prognostic Role of Prothrombin Time and Activated Partial Thromboplastin Time in Patients with Newly Diagnosed Multiple Myeloma

Table 3

Characteristics between matched patients with normal and prolonged PT or APTT.

Characteristics	Normal PT and APTT	Lengthened PT and APTT	value
	(%)	(%)
	Age
≤65 years	48 (62.3)	52 (67.5)	0.499
>65 years	29 (37.7)	25 (32.5)
Light chain
κ	40 (51.9)	43 (55.8)	0.628
λ	37 (48.1)	34 (44.2)
ISS stage
I	10 (13.0)	13 (16.9)	0.638
II	30 (39.0)	25 (32.5)
III	37 (48.1)	39 (50.6)
R-ISS stage
I	9 (11.7)	10 (13.0)	0.876
II	53 (68.8)	50 (64.9)
III	15 (19.5)	17 (22.1)
Serum albumin
<35 g/L	40 (51.9)	39 (50.6)	0.872
≥35 g/L	37 (48.1)	38 (49.4)
Serum β2-microglobulin
<3.5 mg/L	22 (28.6)	21 (27.3)	0.857
≥3.5 mg/L	55 (71.4)	56 (72.7)
Hemoglobin
<100 g/L	57 (74.0)	54 (70.1)	0.590
≥100 g/L	20 (26.0)	23 (29.9)
Platelet
	13 (16.9)	9 (11.7)	0.357
	64 (83.1)	68 (88.3)
Serum creatinine
<88.4 μmol/L	45 (58.4)	44 (57.1)	0.870
≥88.4 μmol/L	32 (41.6)	33 (42.9)
Corrected serum calcium
≤2.75 mmol/L	66 (85.7)	66 (85.7)	1.000
>2.75 mmol/L	11 (14.3)	11 (14.3)
Lactate dehydrogenase
<250 U/L	64 (83.1)	66 (85.7)	0.657
≥250 U/L	13 (16.9)	11 (14.3)
Deep and full immunoparesis
Yes	33 (42.9)	36 (46.8)	0.627
No	44 (57.1)	41 (53.2)
Cytogenetic abnormalities by FISH
del(17p13)
Abnormality	8 (10.4)	8 (10.4)	1.000
No abnormality	69 (89.6)	69 (89.6)
t(14; 16)
Abnormality	0 (0.0)	1 (1.3)	0.316
No abnormality	77 (100.0)	76 (98.7)
t(4; 14)
Abnormality	11 (14.3)	14 (18.2)	0.512
No abnormality	66 (85.7)	63 (81.8)
Induction regimes
Bortezomib based	39 (50.6)	44 (57.1)	0.636
IMiD based	10 (13.0)	7 (9.1)
Bortezomib and IMiD based	28 (36.4)	26 (33.8)
ASCT
Yes	16 (20.8)	17 (22.1)	0.844
No	61 (79.2)	60 (77.9)

Abbreviations: PT: prothrombin time; APTT: activated partial thromboplastin time; IMiD: immunomodulatory; ASCT: autologous stem cell transplant.